Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Nivolumab for Recurrent/Metastatic Carcinosarcoma: A Phase II Study with Pretreatment Tumour Microenvironment Profiling (ESMO-IO 2026) - Oct 25, 2026 - Abstract #352P; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available 
Metastases • P2 data • Tumor microenvironment • Carcinosarcoma • Oncology • Sarcoma • Solid Tumor
https://cslide.ctimeetingtech.com/immuno2026/attendee/confcal/print/presentation/342
 
Kum-Hee Yun; Jeeyun Lee; Miso Kim; Su-Jin Shin; Young Han Lee; S eung Hyun Kim; Min Hwan Kim; Gun Min Kim; Jiwoo Park; Yoo Seok Lee; Yoon D. Han; Hyo Song Kim
 
Oct 25, 2026
 
Prev Next